KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accounts Payables: 2009-2025

Historic Accounts Payables for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $14.3 million.

  • Ionis Pharmaceuticals' Accounts Payables rose 58.26% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year increase of 58.26%. This contributed to the annual value of $43.0 million for FY2024, which is 65.07% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Accounts Payables of $14.3 million as of Q3 2025, which was down 37.17% from $22.8 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Accounts Payables registered a high of $43.0 million during Q4 2024, and its lowest value of $5.6 million during Q3 2023.
  • Moreover, its 3-year median value for Accounts Payables was $14.3 million (2025), whereas its average is $17.7 million.
  • In the last 5 years, Ionis Pharmaceuticals' Accounts Payables crashed by 72.67% in 2023 and then surged by 146.67% in 2025.
  • Ionis Pharmaceuticals' Accounts Payables (Quarterly) stood at $11.9 million in 2021, then spiked by 50.55% to $17.9 million in 2022, then spiked by 45.23% to $26.0 million in 2023, then surged by 65.07% to $43.0 million in 2024, then surged by 58.26% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $22.8 million for Q2 2025, and $17.5 million during Q1 2025.